EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. (Nasdaq: EYPT) announced its participation in three upcoming investor conferences: Stifel 2026 Virtual Ophthalmology Forum, Jefferies Global Healthcare Conference, and Goldman Sachs 47th Annual Global Healthcare Conference. Management will provide fireside chats at each event in late May and early June 2026. The company is developing DURAVYU™, an investigational sustained delivery treatment for serious retinal diseases, with topline data for wet AMD expected in mid-2026.
EyePoint lines up Goldman Sachs, Jefferies, Stifel fireside chats
EyePoint (Nasdaq: EYPT) announced that its management will participate in three upcoming investor conferences. The company will hold fireside chats at the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference in late May and early June 2026. Webcasts and replays of these events will be available on EyePoint's investor relations website.
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. (Nasdaq: EYPT) announced its participation in three upcoming investor conferences: the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026; the Jefferies Global Healthcare Conference on June 3, 2026; and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The company will conduct fireside chats at each event, with webcasts available through its investor relations website. EyePoint is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU™ currently in Phase 3 trials for wet AMD and DME.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to eight new employees as inducement awards, totaling 158,100 shares. These grants comply with NASDAQ Listing Rule 5635(c)(4), with an exercise price of $12.35 per share, vesting over four years. The company is focused on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU™ currently in Phase 3 trials.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to eight new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options cover an aggregate of 158,100 shares of EyePoint common stock, with an exercise price of $12.35 per share. The awards vest over four years, subject to continued employment, and are intended to attract and retain talent for the company, which focuses on developing therapeutics for serious retinal diseases.
EyePoint hands new hires 158,100 stock options at $12.35
EyePoint (Nasdaq: EYPT) granted 158,100 non-statutory stock options to eight new employees as inducement awards, under NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $12.35 per share, a ten-year term, and will vest over four years, with 25% vesting on the first anniversary and the remainder monthly. This move reflects the company's ongoing hiring efforts amid its late-stage DURAVYU development.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to eight new employees as inducement awards, under NASDAQ Listing Rule 5635(c)(4). These options, totaling 158,100 shares, have an exercise price of $12.35 per share and vest over four years, with an initial 25% vesting on the first anniversary of the grant date. This initiative aims to attract and retain talent for the clinical-stage biopharmaceutical company focused on retinal diseases.
EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review
EyePoint Pharmaceuticals received a third consecutive positive safety recommendation for its Phase 3 DURAVYU trials in wet AMD, boosting confidence ahead of mid-2026 topline data. The independent Data and Safety Monitoring Committee (DSMC) reviewed unblinded safety data from the first 200 patients and recommended continuing the trials without modification. Analysts maintain a Buy consensus with a $31.80 price target, implying a significant upside for the stock.
EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review
EyePoint Pharmaceuticals announced that its two Phase 3 clinical trials for EYP-1901, an investigational treatment for wet age-related macular degeneration, have successfully cleared their first safety review by an independent Data Monitoring Committee. The committee found no safety concerns, allowing the trials to continue as planned. This brings the company closer to potentially offering a new, long-acting treatment option for patients.
Third positive DSMC review backs EyePoint (EYPT) Phase 3 DURAVYU wet AMD trials
EyePoint, Inc. (EYPT) announced that its independent Data Safety Monitoring Committee (DSMC) issued a third consecutive positive recommendation for the Phase 3 DURAVYU program for wet age-related macular degeneration (wet AMD), allowing the LUGANO and LUCIA trials to continue without modification. The company reported a favorable safety profile for DURAVYU, consistent across previous trials, with over 35% of treatment-arm patients having received a third dose by Week 56. Topline data for wet AMD is expected to begin in mid-2026, and Phase 3 trials for diabetic macular edema (DME) are also underway with data anticipated in the second half of 2027.
EyePoint’s wet AMD trial continues after safety review
EyePoint, Inc. announced that its Phase 3 trials for DURAVYU, a wet AMD treatment, will continue without modifications after an independent safety review. The company noted a favorable safety profile and reached significant dosing milestones for patients. EyePoint expects topline data from its LUGANO trial in mid-2026 and faces challenges with cash burn despite a strong balance sheet, missing Q1 2026 financial forecasts.
EyePoint Announces Third Consecutive Positive DSMC
EyePoint, Inc. announced that its independent Data Safety Monitoring Committee (DSMC) has given a third consecutive positive recommendation for the Phase 3 wet AMD trials of DURAVYU. The trials, LUGANO and LUCIA, will continue as planned without modification, reinforcing confidence in the drug's safety profile ahead of topline data expected mid-2026. DURAVYU is being evaluated as a potential first-in-class, sustained-delivery treatment for wet age-related macular degeneration, aiming to reduce treatment burden with six-month redosing.
Adage Capital files amendment: 3,300,000 shares in EyePoint (EYPT) disclosed
Adage Capital Management and its affiliated reporting persons have filed an amended Schedule 13G/A, disclosing beneficial ownership of 3,300,000 shares of EyePoint, Inc. (EYPT) common stock, which represents 3.96% of the class. The filing indicates shared voting and dispositive power over these shares by Adage entities and individuals Robert Atchinson and Phillip Gross. This passive disclosure is based on EyePoint's 83,431,950 shares outstanding as of February 27, 2026.
TradingKey
This page provides an overview of EyePoint Pharmaceuticals Inc. (EYPT) on TradingKey, displaying its current stock price, market capitalization, and a loss P/E TTM ratio. It includes sections for company overview, financials, discussions, and analysis, along with a comments section. The content is primarily a stock ticker page.
EyePoint Pharmaceuticals stock (US30233B1098): Trading at discount to fair value estimates
EyePoint Pharmaceuticals (EYPT) shares are reportedly trading at a significant discount to analyst fair value estimates, potentially offering an opportunity for investors. The biotech company specializes in ophthalmology therapeutics, leveraging its Durasert technology for sustained-release treatments for serious eye diseases. With products like YUTIQ and DEXYCU already commercialized, and pipeline assets in advanced clinical stages, EyePoint Pharmaceuticals is positioned as a key player in the growing US ophthalmology market.
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
Mizuho Securities analyst Graig Suvannavejh has reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT) with a $36.00 price target. This recommendation comes despite the company reporting a significant GAAP net loss for the last quarter. However, corporate insider sentiment on the stock is currently negative, with increased selling of shares by insiders.
Is It Too Late To Consider EyePoint (EYPT) After A 133% One-Year Surge?
EyePoint (EYPT) has seen a 133% surge over the past year. Despite recent declines, a Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 84.3%, with an estimated intrinsic value of $86.91 per share compared to its current trading price of $13.66. However, its Price-to-Book ratio of 4.97x is higher than the industry average, indicating mixed valuation signals.
RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating
RBC Capital updated its price target for EyePoint Pharmaceuticals (EYPT) to $37 from $39, while maintaining an Outperform Speculative-Risk rating. This adjustment comes alongside a separate report on Unity Software's fourth-quarter earnings, which showed a significant revenue increase year-over-year. The article primarily reports on analyst rating changes and mentions another company's financial results.
RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating
RBC Capital has adjusted its price target for EyePoint Pharmaceuticals (EYPT) to $37, down from $39, while maintaining an "Outperform Speculative-Risk" rating for the stock. This update reflects a revised valuation perspective from the firm on the biopharmaceutical company, which focuses on developing treatments for serious retinal diseases. The article also mentions recent news regarding EyePoint, including its Q1 2026 earnings call and a complaint filed against Ocular alleging false claims.
EyePoint Pharmaceuticals Shares Fall as Q1 Loss Widens, Revenue Decreases
EyePoint Pharmaceuticals' shares dropped following its first-quarter financial results, which reported a wider loss and decreased revenue. Separately, Unity Software's fourth-quarter revenue increased 35% year-over-year to $609 million, exceeding estimates, despite reporting a quarterly loss of 66 cents per share.
Eyepoint Pharmaceuticals posts Q1 2026 results as pivotal Phase 3 trial reaches new milestone
Eyepoint Pharmaceuticals has released its financial results for the first quarter of 2026, highlighting corporate performance and significant progress in its pivotal Phase 3 clinical trials. The company's report also outlined additional updates on corporate initiatives and growth, signaling ongoing momentum in its development pipeline. Investors can access further details on these developments through the provided link.
Earnings call transcript: Eyepoint Pharmaceuticals misses Q1 2026 EPS and revenue forecasts
EyePoint Pharmaceuticals reported a challenging Q1 2026, missing both EPS and revenue forecasts, posting an EPS of -$0.99 against an expected -$0.82, and revenue of $0.7 million compared to a forecasted $1.01 million. Despite the financial miss, the stock saw a pre-market increase of 2.28%, closing at $14.064, with investors seemingly optimistic about the company's strong cash position and promising clinical pipeline for its lead product, DURAVYU. The company is transitioning to a clinical-stage focus, extensively investing in Phase III trials for DURAVYU for wet AMD and DME, with cash reserves expected to fund operations through Q4 2027.
EyePoint Pharmaceuticals Q1 net loss widens on increased R&D spending
EyePoint Pharmaceuticals reported a widened net loss for the first quarter due to increased spending on research and development. The article, provided by Reuters/Refinitiv, is a concise news brief on the company's financial performance.
EyePoint Pharmaceuticals Announces First Quarter 2026 Financial Results
EyePoint Pharmaceuticals has released its financial results for the first quarter of 2026, detailing key financial figures such as revenue, expenses, and net income. The announcement also covered significant corporate developments, including updates on research and development, regulatory milestones, and strategic partnerships. This report provides a comprehensive overview of the company's financial health and operational advancements during the quarter.
EyePoint (NASDAQ: EYPT) widens Q1 2026 loss while funding DURAVYU Phase 3
EyePoint, Inc. reported a wider net loss of $84.8 million for Q1 2026, or ($0.99) per share, compared to a $45.2 million loss in the prior year, primarily due to increased investment in its DURAVYU Phase 3 trials for wet AMD and DME. Total revenue significantly decreased to $0.7 million as deferred license revenue from YUTIQ rights recognized in the previous year was not repeated. Despite the increased spending, the company maintains a cash runway into Q4 2027, beyond anticipated DURAVYU Phase 3 wet AMD milestones expected to begin mid-2026.
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EyePoint, Inc. announced its first quarter 2026 financial results, with total net revenue of $0.7 million and a net loss of $84.8 million. The company is advancing its Phase 3 trials for DURAVYU in wet AMD and DME, with topline data for wet AMD expected to begin mid-2026. EyePoint also reported cash and investments of $223 million, projecting a financial runway into Q4 2027.
EyePoint Pharmaceuticals Shares Fall as Q1 Loss Widens, Revenue Decreases
EyePoint Pharmaceuticals reported a widening loss and decreasing revenue in Q1 2026, leading to a fall in its share price. The company posted a Q1 loss of $0.99 per share, exceeding analyst estimates, despite revenue of $696,000, which surpassed expectations. EyePoint is currently focused on developing DURAVYU, an investigational treatment for serious retinal diseases, which is in Phase III trials.
Eyepoint Pharma earnings up next as burn rate takes focus
Eyepoint Pharmaceuticals Inc. is set to report its first-quarter results, with analysts anticipating a loss of 82 cents per share on $1.01 million in revenue. Investors will be closely watching the company's cash position and spending as it focuses on advancing its lead investigational drug candidate, DURAVYU, for wet age-related macular degeneration and diabetic macular edema. The company aims to provide updates on its clinical trials and ensure its cash runway into Q4 2027 is sufficient to support these efforts.
H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress
H.C. Wainwright increased its price target for EyePoint Inc. (NASDAQ:EYPT) to $30 from $23, maintaining a Buy rating after the company announced the first patients were dosed in its Phase 3 trials for DURAVYU in diabetic macular edema. The firm now estimates EyePoint's market value at $2.51 billion. Despite reporting significant losses for Q4 and full-year 2025, EyePoint's stock has surged, though InvestingPro analysis suggests it may be overvalued currently.
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Analysts
Eight research firms have given Eyepoint Pharmaceuticals (NASDAQ:EYPT) a consensus "Buy" rating, with an average one-year price target of $32.20. Despite recent missed quarterly earnings estimates, institutional investors such as Janus Henderson, Paradigm Biocapital, and Orbimed Advisors have acquired significant stakes, indicating strong institutional confidence. Insiders also maintain a 4.46% ownership in the biopharmaceutical company which focuses on therapies for ocular diseases.
Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday
Eyepoint Pharmaceuticals (NASDAQ:EYPT) is scheduled to release its Q1 2026 earnings before market open on Wednesday, May 6th. Analysts anticipate a loss of ($0.79) per share on revenue of $0.353 million. Despite missing previous estimates and showing weak financials, analysts have a "Buy" rating with a consensus price target of $32.20, significantly above its current trading price of $13.47.
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
EyePoint, Inc. (Nasdaq: EYPT) announced it will report its first quarter 2026 financial results and discuss corporate developments on May 6, 2026, at 8:30 a.m. ET via a conference call and live webcast. The company is a clinical-stage biopharmaceutical firm focused on developing innovative therapeutics for serious retinal diseases, with its lead candidate DURAVYU currently in Phase 3 trials for wet AMD and DME. Topline data for wet AMD is expected in mid-2026.
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
EyePoint, Inc. announced it will report its first quarter 2026 financial results and provide corporate updates on a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 6, 2026. The company is focused on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU™ currently in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. EyePoint expects topline data for wet AMD in mid-2026.
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
EyePoint, Inc. will host a conference call and live webcast on Wednesday, May 6, 2026, at 8:30 a.m. ET to announce its first quarter 2026 financial results and discuss recent corporate developments. The company is a clinical-stage biopharmaceutical firm focused on innovative therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, currently in Phase 3 pivotal trials for wet AMD and DME. Topline data for wet AMD is expected in mid-2026.
EyePoint (NASDAQ: EYPT) plans virtual 2026 meeting and larger equity pool
EyePoint, Inc. (NASDAQ: EYPT) will hold its 2026 annual meeting virtually on June 18, 2026, where stockholders will vote on key governance items, including the election of eight directors and an increase of 4,900,000 shares to the 2023 Long-Term Incentive Plan. The company highlighted strong 2025 clinical progress with DURAVYU in wet AMD and diabetic macular edema, expecting topline data for wet AMD in mid-2026 and DME in Q4 2027. This share increase is crucial for attracting and retaining talent in a competitive market, ensuring the continuation of their equity incentive program.
Insider Selling: Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Sells 2,437 Shares of Stock
Eyepoint Pharmaceuticals (NASDAQ:EYPT) insider Ramiro Ribeiro sold 2,437 shares of stock for a total of $36,555.00 on April 17th. The company recently missed its quarterly earnings estimates, reporting ($0.81) EPS against a consensus of ($0.78), and also missed revenue expectations. Despite the sales and earnings miss, analysts have a consensus "Buy" rating and an average price target of $32.20 for EYPT.
EyePoint (Nasdaq:EYPT) - Stock Analysis
This Simply Wall St analysis provides a detailed look at EyePoint, Inc. (Nasdaq:EYPT), a pharmaceutical company developing therapeutics for retinal diseases. It highlights that the stock is considered 61.7% undervalued by analysts, with a forecast revenue growth of 53.99% per year, despite being currently unprofitable and having experienced shareholder dilution. The report also covers recent news, price performance, and fundamental statistics, including a market cap of US$1.2 billion and a negative P/E ratio.
Understanding Momentum Shifts in (EYPT)
The article analyzes Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), indicating strong sentiment across all time horizons supporting an overweight bias. It highlights a mid-channel oscillation pattern and an exceptional 74.7:1 risk-reward setup targeting a 21.9% gain with minimal risk. The analysis also provides three distinct AI-generated trading strategies for different risk profiles.
EyePoint CMO Ramiro Ribeiro sells $36,555 in company shares By Investing.com
EyePoint's Chief Medical Officer, Ramiro Ribeiro, sold 2,437 shares of the company's common stock for $36,555 after exercising stock options on April 17, 2026. This transaction leaves him with no directly held shares but 80,438 stock options. The sale occurred despite the stock's 163% return over the past year, with InvestingPro data valuing it near its fair value of $14.57.
Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD
EyePoint Pharmaceuticals has completed patient enrollment for its Phase III clinical program evaluating Duravyu (EYP-1901) for the treatment of wet age-related macular degeneration (wet AMD). The program includes two pivotal trials, LUMINARY and VERONA, which are assessing the efficacy and safety of Duravyu, an investigational sustained-release anti-VEGF treatment. Topline data from the LUMINARY trial is expected in the second half of 2026.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced it granted non-statutory stock options to 14 new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4). These options, totaling 362,500 shares, were granted on April 15, 2026, with an exercise price of $14.63 per share and a four-year vesting schedule. The grants were approved by the Compensation Committee to incentivize new hires.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to fourteen new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options cover 362,500 shares of EyePoint common stock, with an exercise price of $14.63 per share, vesting over four years. The company is focused on developing and commercializing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, currently in Phase 3 trials.
EyePoint hires 14 employees, grants 362,500 stock options
EyePoint (Nasdaq: EYPT) has granted non-statutory inducement stock options for an aggregate of 362,500 shares to fourteen new employees, effective April 15, 2026. The options have an exercise price of $14.63, a 10-year term, and vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments. These grants were approved by the Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4).
JPMorgan Chase & Co. Sells 217,150 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT
JPMorgan Chase & Co. significantly reduced its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 87.8% in the third quarter, selling 217,150 shares and retaining 30,262 shares valued at $431,000. Despite this sell-off, Wall Street analysts largely maintain a bullish stance with an average "Buy" rating and a consensus price target of $32.20. The company's fundamentals currently appear weak, having reported a quarterly EPS miss of ($0.81), negative net margin, and negative return on equity, with shares trading around $14.34.
DURAVYU Phase 3 plans and cash runway outlined by EyePoint (EYPT)
EyePoint, Inc. (EYPT) filed an 8-K detailing its updated investor presentation for DURAVYU, a sustained-release tyrosine kinase inhibitor for retinal disease. The presentation outlines Phase 3 programs for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), with topline wet AMD data expected in mid-2026. The company also reported approximately $220 million in cash and investments as of March 31, 2026, which is projected to fund operations into the fourth quarter of 2027.
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
EyePoint Pharmaceuticals provided an update on its DURAVYU Phase 3 trials for wet AMD and DME, confirming full enrollment for wet AMD trials with data expected mid-2026, and DME trial enrollment completion by Q3 2026. The company also reported a substantial cash runway into late 2027 and is advancing manufacturing scale-up for DURAVYU, positioning it for the large retinal anti-VEGF market. EyePoint (EYPT) currently holds a "Neutral" rating from Spark's AI Analyst, despite positive pipeline developments, due to financial performance concerns.
Avoiding Lag: Real-Time Signals in (EYPT) Movement
This article analyzes Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) using predictive AI, highlighting a strong near-term sentiment shifting to a long-term positive bias. It presents an exceptional 77.3:1 risk-reward setup targeting a 22.7% gain with minimal risk and outlines specific position, momentum, and risk-hedging trading strategies developed by AI models for different risk profiles.
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by Brokerages
Eyepoint Pharmaceuticals (NASDAQ:EYPT) has received a "Buy" consensus recommendation from eight brokerages, with an average 12-month price target of $32.20. Despite recent weak quarterly results and negative profitability metrics, several firms, including Citigroup and HC Wainwright, have raised their price targets. Institutional investors hold a significant 99.41% stake in the company.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.7% - Time to Sell?
Eyepoint Pharmaceuticals (NASDAQ:EYPT) saw its stock price fall by 3.7% to $12.90 on Monday, with a significant 94% drop in trading volume compared to its average. Despite weak company fundamentals, including missed quarterly earnings and revenue expectations, analysts largely maintain a "Buy" rating with a consensus target price of $32.20. Institutional investors have been actively adjusting their positions, with several major firms increasing their stakes in the biopharmaceutical company.
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
Aberdeen Group plc significantly increased its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 101.6% in the fourth quarter, bringing its total holdings to 1,605,984 shares valued at approximately $29.34 million. This move highlights strong institutional interest, with 99.41% of the company's shares owned by institutional investors. Despite recent EPS misses and negative profitability, the stock maintains an average "Buy" rating from analysts with a mean target price of $32.20.
